At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Apr 19, 2026 at 18:00 ET
Xenon Pharmaceuticals presented positive Phase 3 X-TOLE2 and long-term open-label data for azetukalner in focal onset seizures at the AAN 2026 meeting, showing statistically significant and durable seizure reduction, with nearly 40% of long-term patients achieving at least 12 months of seizure freedom. The company plans to submit an NDA to the FDA in Q3 2026.
- Azetukalner 25 mg achieved a 53.2% reduction in monthly seizure frequency vs. 10.4% for placebo (p<0.0001) in the Phase 3 X-TOLE2 trial.
- Long-term data from the X-TOLE OLE study show 38.2% of patients treated for ≥48 months achieved at least 12 months of seizure freedom.
- Azetukalner demonstrated consistent safety with low rates of serious adverse events (5.6% in 25 mg group vs. 2.4% placebo).
- Xenon plans to submit an NDA for azetukalner in epilepsy to the FDA in Q3 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access